Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1363641 | 1.00 | AR (0.42) | ARPGRNR3C1SMN1; SMN2CTSL | |
| SCHEMBL15712960 | 0.92 | AR (0.38) | ARPGRNR3C1SMN1; SMN2CTSL | |
| SCHEMBL12307978 | 0.92 | AR (0.43) | ARPGRNR3C1SMN1; SMN2S1PR1 | |
| SCHEMBL1363718 | 0.92 | AR (0.43) | ARPGRNR3C1SMN1; SMN2S1PR1 | |
| SCHEMBL1363767 | 0.92 | AR (0.43) | ARPGRNR3C1S1PR3NR3C2 | |
| SCHEMBL1363222 | 0.92 | AR (0.43) | ARPGRNR3C1SMN1; SMN2S1PR1 | |
| SCHEMBL1364665 | 0.92 | AR (0.43) | ARPGRNR3C1S1PR3NR3C2 | |
| SCHEMBL1365820 | 0.91 | AR (0.52) | ARPGRNR3C1S1PR3 | |
| SCHEMBL1364632 | 0.91 | AR (0.52) | ARPGRNR3C1S1PR3 | |
| SCHEMBL14917510 | 0.90 | AR (0.41) | ARPGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260028-B1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8629167-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629167-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8455525-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455525-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8268872-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268872-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8067448-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067448-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253758-A1 | Selective androgen receptor modulators | ELLIPSES PHARMA LTD (GB) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041721-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, IGF1R | AR 1/4885PGR 16/4885NR3C1 70/4885 |
| US-20110224267-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | AR 1/4885PGR 28/4885NR3C1 57/4885 |
| US-20130116288-A1 | Selective Androgen Receptor Modulators | AR, SHBG, IGF1R | AR 1/4885PGR 17/4885NR3C1 58/4885 |
| US-20090253758-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | AR 1/4885PGR 28/4885NR3C1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.